Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2006-06-20
2006-06-20
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S184100, C424S185100, C424S278100, C514S002600, C514S013800, C514S012200, C514S885000, C530S324000, C530S325000, C530S326000
Reexamination Certificate
active
07063854
ABSTRACT:
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
REFERENCES:
patent: 5350840 (1994-09-01), Call et al.
patent: 5633142 (1997-05-01), Herlyn et al.
patent: 5670317 (1997-09-01), Ladanyi et al.
patent: 5693522 (1997-12-01), Chada et al.
patent: 5726288 (1998-03-01), Call et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6096313 (2000-08-01), Jager et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 6316599 (2001-11-01), Call et al.
patent: 1004319 (2000-05-01), None
patent: 1103564 (2001-05-01), None
patent: 11-89596 (1999-04-01), None
patent: 11-89599 (1999-04-01), None
patent: WO 91/07509 (1991-05-01), None
patent: WO 94/21287 (1994-09-01), None
patent: 95/06725 (1995-03-01), None
patent: 95/29995 (1995-11-01), None
patent: WO 96/38176 (1996-12-01), None
patent: WO 99/03506 (1999-01-01), None
patent: 99/58135 (1999-11-01), None
patent: WO 00/06602 (2000-02-01), None
patent: WO 00/18795 (2000-04-01), None
patent: WO 01/60970 (2001-08-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/00677 (2002-01-01), None
Boon, Int. J Cawlyn, 54:177-180, 1993.
Menke et al., “Wilms' Tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells,”Oncogene 12: 537-546, 1996.
Yamagami et al., “Growth Inhibition of Human Leukemic Cells by WT1 (Wilms Tumor Gene) Antisene Oligodeoxynucleotides: Implications for the Involvement of WT1 in Leukemogenesis,”Blood 87(7): 2878-2884, 1996.
Mundlos et al., “Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues,”Development 119: 1329-1341, 1993.
Kudoh et al., “G1phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes,”Proc. Natl. Acad. Sci. USA 92: 4517-4521, 1995.
Ramani and Cowell, “The Expression Pattern Of Wilms' Tumour Gene (WT1) Product In Normal Tissues And Paediatric Renal Tumours,”Journal Of Pathology 179: 162-168, 1996.
Menssen et al., “Wilms' Tumor Gene Expression in Human CD34 Hematopoietic Progenitors During Fetal Development and Early Clonogenic Growth,”Blood 89(9): 3486-3487, 1997 (letter).
Call et al., “Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus,”Cell 60: 509-520, 1990.
Telerman et al., “Identification of the cellular protein encoded by the human Wilms' tumor (WT1) gene,”Oncogene 7:2545-2548, 1992.
Sharma et al., “Molecular Cloning of Rat Wilms' Tumor Complementary DNA and a Study of Messenger RNA Expression in the Urogenital System and the Brain,”Cancer Research 52: 6407-6412, 1992.
Wang et al., “The Wilms' Tumor Gene Product, WT1, Represses Transcription of the Platelet-derived Growth Factor A-chain Gene,”The Journal Of Biological Chemistry 267(31): 21999-22002, 1992.
Tadokoro et al., “Genomic Organization of the Human WT1 Gene,”Jpn. J. Cancer Res. 83: 1198-1203, 1992.
Haber et al., “A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells,”Proc. Natl. Acad. Sci. USA 89:6010-6014, 1992.
Inoue et al., “WT1 as a New Prognostic Factor and a New Marker for the Detection of Minimal Residual Disease in Acute Leukemia,”Blood 84:3071-3079, 1994.
Tsurutani et al., “cDNA cloning and developmental expression of the porcine homologue of WT1,”Gene 211(2): 215-220, 1998.
Huang et al., “Tissue, Developmental, and Tumor-Specific Expression of Divergent Transcripts in Wilms Tumor,”Science 250: 991-994, 1990.
Phelan et al., “Wilms' Tumor Gene, WT1, mRNA Is Down-regulated during Induction of Erythroid and Megakaryocytic Differentiation of K562 Cells,” Cell Growth & Differentiation 5: 677-686, 1994.
Sekiya et al., “Downregulation of Wilms' Tumor Gene (wt1) During Myelomonocytic Differentiation in HL60 Cells,”Blood 83(7): 1876-1882, 1994.
Brieger et al., “The Expression of the Wilms' Tumor Gene in Acute Myelocytic Luekemias as Possible Marker for Leukemia Blast Cells,”Leukemia 8(12): 2138-2143, 1994.
Pritchard-Jones et al., “The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient,”Human Molecular Genetics 3(9): 1633-1637, 1994.
Tadokoro et al., “Intragenic homozygous delection of the WT1 gene in Wilms' tumor,”Oncogene 7: 1215-1221, 1992.
Armstrong et al., “The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo,”Mechanisms of Development 40: 85-97, 1992.
Wang et al., “The Wilms' Tumor Gene Product WT1 Activates or Suppresses Transcription through Separate Functional Domains,”The Journal Of Biological Chemistry 268(13): 9172-9175, 1993.
Wang et al., “A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1,”Proc. Natl. Acad. Sci. USA 90: 8896-8900, 1993.
Rauscher, “The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor,”FASEB J. 7: 896-903, 1993.
Harrington et al., “Inhibition of Colony-stimulating Factor-1 Promoter Activity by the Product of the Wilms' Tumor Locus,”The Journal Of Biological Chemistry 268(28): 21271-21275, 1993.
Tadokoro et al., “PCR Detection of 9 Polymorphisms in the WT1 Gene,”Human Molecular Genetics 2(12): 2205-2206, 1993.
Tadokoro et al., “Taq1 RFLPs at the Wilms' tumor gene (WT1),”Nucleic Acids Research 19(9): 2514, 1991.
Kreidberg et al., “WT-1 Is Required for Early Kidney Development,”Cell 74: 679-691, 1993.
Miyagi et al., “Expression of the Candidate Wilms' Tumor Gene, WT1, in Human Leukemia Cells,”Leukemia 7(7): 970-977, 1993.
Brenner et al., “RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms' tumors,”Oncogene 7: 1431-1433, 1992.
Rupprecht et al., “The Wilms' Tumor Suppressor Gene WT1 Is Negatively Autoregulated,”The Journal Of Biological Chemistry 269(8): 6198-6206, 1994.
Wang et al., “WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein,”Oncogene 10(6): 1243-1247, 1995.
Wu et al., “GATA-1 Transactivates the WT1 Hematopoietic Specific Enhancer,”The Journal Of Biological Chemistry 270(11): 5944-5949, 1995.
Brieger et al., “The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR,”Annals of Oncology 6: 811-816, 1995.
Hamilton et al., “High affinity binding sites for the Wilms' tumour suppressor protein WT1,”Nucleic Acids Research 23(2): 277-284, 1995.
Reddy et al., “WT1-mediated Transcriptional Activation Is Inhibited by Dominant Negative Mutant Proteins,”The Journal Of Biological Chemistry 270(18): 10878-10884, 1995.
Nichols et al., “WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells,”Cancer Research 55: 4540-4543, 1995.
Luo et al., “The tumor suppressor gene WT1 inhibits ras-mediated transformation,”Oncogene 11: 743-750, 1995.
Goodyer et al., “Repression of the retinoic acid receptor-α gene by the Wilms' tumor suppressor gene product, wt1,”Oncogene 10: 1125-1129, 1995.
King-Underwood et al., “Mutations in the Wilms' Tumor Gene WT1 in Leukemias,”Blood 91: 2961-2968, 1998.
Patmasi
Cheever Martin A.
Gaiger Alexander
Corixa Corporation
Schwadron Ronald B.
Seed IP Law Group PLLC
University of Washington
LandOfFree
Composition and methods for WTI specific immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and methods for WTI specific immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and methods for WTI specific immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695348